Among patients with APL, 47.9% carry FLT3 mutations [31], and it has been shown that PML–RARA fusion can collaborate with FLT3 mutation to induce an APL-like disease in the mouse [32]. This evidence concerns the gene FLT3 and acute promyelocytic leukemia.